Addressing influenza vaccine effectiveness: cell-based influenza vaccine technology as an option

This webinar is for UK HCPs only and has been developed and organised by Seqirus.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events relating to Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.

Click below for prescribing information;

Flucelvax® Tetra , Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) prescribing information https://labeling.seqirus.com/API/UK/Flucelvax-Tetra/EN/Flucelvax-Tetra-Prescribing-Information.pdf